Benefits of Moderna and Merck melanoma vaccine plus Keytruda extend to
three years

An experimental messenger RNA cancer vaccine developed by Moderna
(MRNA.O), and Merck & Co (MRK.N), paired with Merck's Keytruda cut the
chance of recurrence or death from melanoma by half after three years,
showing that benefits demonstrated a year ago have held up over time.
...
...
The vaccine is custom-built based on an analysis of a patient's tumors
after surgical removal. The vaccines are designed to train the immune
system to recognize and attack specific mutations in cancer cells.
...
...
The combination treatment has won U.S. breakthrough therapy and
European Medicines Agency PRIME scheme designations, regulatory
programs that aim to speed development of innovative treatments.
Still, Hoge said that even with the new data it would be some time
before the companies can file for approval of the treatment.

https://www.reuters.com/business/healthcare-pharmaceuticals/benefits-moderna-merck-melanoma-vaccine-plus-keytruda-extend-three-years-2023-12-14/

--- SoupGate-Win32 v1.05
* Origin: fsxNet Usenet Gateway (21:1/5)